ANDA 206181, held by Ajanta Pharma. Voriconazole.
As of Nov 21, 2026, ANDA 206181 (Voriconazole), held by Ajanta Pharma, was first approved by FDA on May 24, 2016, with 11 approved supplements and 0 published complete response letters.
Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis Candidemia in non-neutropenics and other deep tissue Candida infections Esophageal candidiasis Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy 1.1 Invasive Aspergillosis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 24, 2016 | Original application | Approved | None posted |
| Voriconazole50MG · tablet;oral | Voriconazole | Rx |
| Voriconazole200MG · tablet;oral | Voriconazole | Rx |
| Nov 16, 2026 | Supplement 32Labeling · Standard review | Approved | None posted |
| Sep 26, 2025 | Supplement 31Labeling · Standard review | Approved | None posted |
| Nov 29, 2022 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 29, 2022 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jun 13, 2022 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jun 13, 2022 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jul 16, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jul 16, 2021 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 16, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 8, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 8, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 24, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters